Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
K36 Therapeutics
AddedFeb 17, 2024
UpdatedJun 18, 2026
K36 Therapeutics

K36 Therapeutics

K36 Therapeutics: Pioneering small molecule therapies via epigenetic modulation of cancer pathways.

HQ
Cambridge, MA, US
Founded
2021
Overview
Compare
Fundraising
Employees
Website

Founded with a mission to revolutionize cancer treatment, K36 Therapeutics focuses on developing first-in-class small molecule therapies through the epigenetic modulation of oncogenic pathways. Their primary market focus is on patients with multiple myeloma, a type of blood cancer. The company's lead candidate, KTX-, is a selective inhibitor of the histone methyltransferase MMSET, which is overexpressed in a significant percentage of multiple myeloma cases due to a specific genetic translocation.

Notable affiliated individuals and investors include leading experts in oncology and epigenetics, although specific names are not provided. K36 Therapeutics has achieved significant milestones, including the initiation of clinical trials for their lead candidate, KTX-. Their work has the potential to change the treatment landscape for multiple myeloma patients by targeting the underlying genetic causes of the disease, thus offering a more effective and personalized therapeutic option.

K36 Therapeutics - Similar Companies

Kestrel Therapeutics logo

Kestrel Therapeutics

Karyopharm Therapeutics logo

Karyopharm Therapeutics

karyopharm.com

Synnovation Therapeutics logo

Synnovation Therapeutics

synnovationtx.com

Triplet Therapeutics logo

Triplet Therapeutics

triplettx.com

Flare Therapeutics logo

Flare Therapeutics

flaretx.com

TenSixty Biosciences logo

TenSixty Biosciences

tensixty.bio

Dual Therapeutics logo

Dual Therapeutics

NiKang Therapeutics logo

NiKang Therapeutics

KSQ Therapeutics logo

KSQ Therapeutics

ksqtx.com

Window Therapeutics logo

Window Therapeutics

windowtx.com

Telo Therapeutics logo

Telo Therapeutics

NKT Therapeutics logo

NKT Therapeutics

Kurome Therapeutics logo

Kurome Therapeutics

PanTher Therapeutics logo

PanTher Therapeutics

panthertx.com

Affigen logo

Affigen

affigen.com

K36 Therapeutics - Quick Facts

Who are K36 Therapeutics' competitors?

Companies similar to K36 Therapeutics include Kestrel Therapeutics, Karyopharm Therapeutics, Synnovation Therapeutics and Triplet Therapeutics.

When was K36 Therapeutics founded?

K36 Therapeutics was founded in 2021.

Where is K36 Therapeutics' headquarters located?

K36 Therapeutics' headquarters is located in Cambridge, MA, US.

When was K36 Therapeutics' last funding round?

K36 Therapeutics' most recent funding round was for $70M (USD) in June 2023.

How much has K36 Therapeutics raised to-date?

As of Jun 28, 2023, K36 Therapeutics has raised a total of $100M (USD).

How many employees does K36 Therapeutics have?

K36 Therapeutics has 8 employees as of Feb 4, 2024.

K36 Therapeutics - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Americas
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Cancer Therapies
Tags
  • Biotech
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 12 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified